ClinicalTrials.gg
RecruitingNCT07619079Updated Nov 20, 2026

Malignant Polyp Registry

An observational study in Malignant Colorectal Polyp, Colorectal Cancer and T1 Colorectal Cancer, sponsored by Memorial Sloan Kettering Cancer Center. Recruiting at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Memorial Sloan Kettering Cancer Center · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Nov 20, 2026Eligibility revisedTitle changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center — 12 open to participants now, 18 under way, none of them phase 3. Colorectal Neoplasms · Memorial Sloan Kettering Cancer Center.

Planned enrollment
3rd of 21
500 · median 110
Started
2026
with 3 others
Observational
21 of 69
5 open now
Primary completion
2029-05
later than 15 of 17 live
Registered
67th of 69
by date

Among the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, this one is the 3rd largest by planned enrollment of the 21 observational ones that give a count, is one of 4 that started in 2026, is one of 21 observational ones, reaches primary completion later than 15 of the 17 other live ones, and was the 67th registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

12 of the 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center are open now, in 6 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Colorectal Neoplasms by Memorial Sloan Kettering Cancer Center, or all of them as a file.
02

Study summary

The purpose of this study is to learn more about malignant colorectal polyps (early colorectal cancers removed during colonoscopy) and the risk that cancer remains, comes back, or spreads after the polyp is removed. The researchers also want to understand how patients and doctors make decisions about whether to have surgery or to be followed closely without surgery after a malignant polyp is removed.

This is an observational study. Participants will not receive any study treatment, and their care will be decided by them and their doctors as usual. The researchers will collect information from participants' medical records, including test results, imaging scans, lab work, and pathology reports, and may collect images from colonoscopy and copies of the pathology slides of the polyp. Participants will be asked to complete short questionnaires about how they view their risk and what influenced their treatment decision. The researchers will follow participants' health over time through their regular doctor visits; if no visit is scheduled, a member of the study team will contact participants by phone at 1, 3, and 5 years after they join the study.

03

Conditions studied

  • Malignant Colorectal Polyp
  • Colorectal Cancer
  • T1 Colorectal Cancer

Keywords

  • PT1
  • early colorectal cancer
  • polypectomy
  • endoscopic submucosal dissection
  • endoscopic mucosal resection
  • surveillance
  • watch and wait
  • organ preservation
  • shared decision-making
  • registry
  • 26-176
04

Who can participate

The criteria were revised on the registry on Nov 20, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults with a single endoscopically resected malignant colorectal polyp (pT1 colorectal cancer) evaluated at Memorial Sloan Kettering Cancer Center. Patients seen in the Colorectal Surgery outpatient clinics at MSK Manhattan and MSK regional sites will be prospectively screened; eligible patients identified in other MSK clinics may also be invited to participate. Patients may enroll regardless of pathologic risk features and regardless of whether they choose surgery or nonoperative surveillance.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or older
  • A single malignant colorectal polyp, defined as a colorectal adenocarcinoma invading the submucosa but not the muscularis propria (pT1), arising in an adenomatous or serrated polyp
  • Endoscopic resection of the malignant polyp by snare polypectomy, endoscopic mucosal resection (EMR), or endoscopic submucosal dissection (ESD)
  • Pathologic confirmation of the malignant polyp within 90 days before enrollment

Exclusion criteria

Exclusion Criteria:

  • Synchronous
  • Hereditary cancer syndromes
  • History of Inflammatory bowel disease
  • More than one malignant polyp
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes

Groups and cohorts

  • Immediate surgery

    patients who choose colorectal resection after endoscopic removal of a malignant polyp

    Other: Questionnaires

  • Nonoperative surveillance

    patients who choose surveillance without surgery

    Other: Questionnaires

Interventions

  • OtherQuestionnaires

    risk-perception/decision-making questionnaire and validated risk-attitude scales, completed once during evaluation (both cohorts)

06

What researchers measure

Primary outcomes

  1. Risk of residual disease and/or recurrent disease

    Residual disease is defined as cancer in the bowel wall or regional lymph nodes found at surgery performed after endoscopic resection (assessed in participants who undergo surgery). Recurrent disease is defined as local or distant reappearance of cancer during follow-up (assessed in all participants). Rates will be estimated using the Kaplan-Meier method with 95% confidence intervals.

    Time frame: Up to 5 years

Secondary outcomes

  1. Disease-free survival

    time from endoscopic removal of the malignant polyp to local recurrence, distant recurrence, or death

    Time frame: Up to 5 years

  2. Overall survival

    time from endoscopic removal to death from any cause

    Time frame: Up to 5 years

  3. Local recurrence rate

    reappearance of cancer at or near the site of the original polyp

    Time frame: Up to 5 years

  4. Distant recurrence rate

    spread of cancer to sites distant from the original polyp

    Time frame: Up to 5 years

  5. Factors associated with patient treatment choice

    association of risk perception, priorities and risk attitudes (study questionnaire, PRT, HRAS-6, DOSPERT-M) with choice of surgery vs surveillance

    Time frame: at enrollment

  6. Accuracy of surgeon risk assessment

    Concordance between surgeons' estimated risk of residual or recurrent disease at diagnosis (before and after multidisciplinary discussion) and observed outcomes

    Time frame: Up to 5 years

07

Study locations

7 of 7 sites recruiting
  • Memorial Sloan Kettering Basking Ridge
    Basking Ridge, New Jersey 07920, United States
    Recruiting
    • Georgios Karagkounis, MD · Contact212-639-2269
  • Memorial Sloan Kettering Monmouth
    Middletown, New Jersey 07748, United States
    Recruiting
    • Georgios Karagkounis, MD · Contact212-639-2269
  • Memorial Sloan Kettering Bergen
    Montvale, New Jersey 07645, United States
    Recruiting
    • Georgios Karagkounis, MD · Contact212-639-2269
  • Memorial Sloan Kettering Suffolk - Commack
    Commack, New York 11725, United States
    Recruiting
    • Georgios Karagkounis, MD · Contact212-639-2269
  • Memorial Sloan Kettering Westchester
    East White Plains, New York 10604, United States
    Recruiting
    • Georgios Karagkounis, MD · Contact212-639-2269
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10065, United States
    Recruiting
    • Georgios Karagkounis, MD · Contact212-639-2269
    • Julio Garcia-Aguilar, MD,PhD · Contact212-639-5117
  • Memorial Sloan Kettering Nassau
    Uniondale, New York 11553, United States
    Recruiting
    • Georgios Karagkounis, MD · Contact212-639-2269
08

References and documents

Individual participant data

Plan to share: Yes — Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made following one year after publication and for up to 36 months later. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for May 2029, 36 months after the start.

Of 531 non-industry observational studies under Colorectal Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 132. This study's planned 36 months is below that.

Counting every sponsor, half of 648 studies reached it within 52 months; a quarter within 27 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Jun 1, 2026
StartActual
May 19, 2026
Primary completionEst.
May 19, 2029
CompletionEst.
May 19, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Memorial Sloan Kettering Westchester · East White Plains, United States
Show 1 removed
  • Memorial Sloan Kettering Westchester · Harrison, United States
Nov 20, 2026
Eligibility
Criteria revised in 4 updates
What changed on Oct 16, 2026
  • AddedExclusion Criteria:
  • AddedA patient will be considered inelligibe for this study if any of the following conditions apply:
  • AddedSynchronous malignancy
  • AddedHereditary cancer syndromes
  • AddedHistory of Inflammatory bowel disease
What changed on Oct 22, 2026
  • RemovedCriteria:
  • RemovedDocumentation of Disease
  • RemovedPatients must have one malignant polyp, pathologically confirmed within 90 days of enrollment. Patients with multiple malignant polyps are not eligible.
  • RemovedDefinition of Disease Colorectal carcinoma (CRC) develops within serrated or adenomatous polyps. Early CRC represents invasion into the submucosa and frequently presents within the precursor polyp which is termed a 'malignant polyp'(23).
  • RemovedThe term malignant polyp specifically refers to a colorectal lesion with cancer invading the submucosa but not extending into the muscularis propria. These lesions are classified as pT1 in the TNM classification system (24)
  • RemovedExclusion Criteria:
  • RemovedA patient will be considered inelligibe for this study if any of the following conditions apply:
  • RemovedSynchronous malignancy
  • RemovedHereditary cancer syndromes
  • RemovedHistory of Inflammatory bowel disease
Inclusion criteria
  • EditedAge ≥ 1818 years or older
  • AddedA single malignant colorectal polyp, defined as a colorectal adenocarcinoma invading the submucosa but not the muscularis propria (pT1), arising in an adenomatous or serrated polyp
  • EditedPrior Treatment Endoscopic resection of the polypoid lesion-malignant polyp with simpleby snare polypectomy, conventional endoscopic mucosal resection (EMR), or endoscopic submucosal dissection (ESD) (25).
  • AddedPathologic confirmation of the malignant polyp within 90 days before enrollment
Exclusion criteria
  • Added- More than one malignant polyp
What changed on Oct 28, 2026
Exclusion criteria
  • Edited- °More than one malignant polyp
What changed on Nov 20, 2026
Exclusion criteria
  • AddedSynchronous malignancy
  • AddedHereditary cancer syndromes
  • AddedHistory of Inflammatory bowel disease
  • Edited°More than one malignant polyp
across 4 updates, Oct 16, 2026 – Nov 20, 2026
Interventions
Arms or interventions changed
Oct 22, 2026
Primary outcomes
1 time frame changed, 1 description edited
What changed in the outcomes
  • Time frameRisk of residual disease and/or recurrent disease5 years → Up to 5 years
  • DescriptionRisk of residual disease and/or recurrent disease: how it is measured was reworded
Oct 22, 2026
Secondary outcomes
Revised in 2 updates
What changed on Oct 22, 2026
  • AddedDisease-free survivalTime frame: Up to 5 years
  • AddedOverall survivalTime frame: Up to 5 years
  • AddedLocal recurrence rateTime frame: Up to 5 years
  • AddedDistant recurrence rateTime frame: Up to 5 years
  • AddedFactors associated with patient treatment choiceTime frame: at enrollment
What changed on Oct 28, 2026
  • AddedAccuracy of surgeon risk assessmentTime frame: Up to 5 years
across 2 updates, Oct 22, 2026 – Oct 28, 2026
Show all 4 updates
  1. Nov 20, 2026
    1 site added, 1 site removed
    Show site
    • Memorial Sloan Kettering Westchester · East White Plains, United States
    Show 1 removed
    • Memorial Sloan Kettering Westchester · Harrison, United States
    Eligibility 1 exclusion criterion edited, 3 added
    What changed in the criteria
    Exclusion criteria
    • AddedSynchronous malignancy
    • AddedHereditary cancer syndromes
    • AddedHistory of Inflammatory bowel disease
    • Edited°More than one malignant polyp
    + 1 other change: verification date
  2. Oct 28, 2026
    Eligibility 1 exclusion criterion edited
    What changed in the criteria
    Exclusion criteria
    • Edited- °More than one malignant polyp
    Secondary outcomes 1 added
    What changed in the outcomes
    • AddedAccuracy of surgeon risk assessmentTime frame: Up to 5 years
    Title A Prospective Registry of Patients With Endoscopically Resected Malignant Colorectal Polyps (pT1 Colorectal Cancer)→Malignant Polyp Registry
  3. Oct 22, 2026
    Eligibility 2 inclusion criteria edited, 2 added; 1 exclusion criterion added; 10 criteria removed
    What changed in the criteria
    • RemovedCriteria:
    • RemovedDocumentation of Disease
    • RemovedPatients must have one malignant polyp, pathologically confirmed within 90 days of enrollment. Patients with multiple malignant polyps are not eligible.
    • RemovedDefinition of Disease Colorectal carcinoma (CRC) develops within serrated or adenomatous polyps. Early CRC represents invasion into the submucosa and frequently presents within the precursor polyp which is termed a 'malignant polyp'(23).
    • RemovedThe term malignant polyp specifically refers to a colorectal lesion with cancer invading the submucosa but not extending into the muscularis propria. These lesions are classified as pT1 in the TNM classification system (24)
    • RemovedExclusion Criteria:
    • RemovedA patient will be considered inelligibe for this study if any of the following conditions apply:
    • RemovedSynchronous malignancy
    • RemovedHereditary cancer syndromes
    • RemovedHistory of Inflammatory bowel disease
    Inclusion criteria
    • EditedAge ≥ 1818 years or older
    • AddedA single malignant colorectal polyp, defined as a colorectal adenocarcinoma invading the submucosa but not the muscularis propria (pT1), arising in an adenomatous or serrated polyp
    • EditedPrior Treatment Endoscopic resection of the polypoid lesion-malignant polyp with simpleby snare polypectomy, conventional endoscopic mucosal resection (EMR), or endoscopic submucosal dissection (ESD) (25).
    • AddedPathologic confirmation of the malignant polyp within 90 days before enrollment
    Exclusion criteria
    • Added- More than one malignant polyp
    Primary outcomes 1 time frame changed, 1 description edited
    What changed in the outcomes
    • Time frameRisk of residual disease and/or recurrent disease5 years → Up to 5 years
    • DescriptionRisk of residual disease and/or recurrent disease: how it is measured was reworded
    Secondary outcomes 5 added
    What changed in the outcomes
    • AddedDisease-free survivalTime frame: Up to 5 years
    • AddedOverall survivalTime frame: Up to 5 years
    • AddedLocal recurrence rateTime frame: Up to 5 years
    • AddedDistant recurrence rateTime frame: Up to 5 years
    • AddedFactors associated with patient treatment choiceTime frame: at enrollment
    Interventions Arms or interventions changed
    Title Malignant Polyp Registry→A Prospective Registry of Patients With Endoscopically Resected Malignant Colorectal Polyps (pT1 Colorectal Cancer)
    + 3 other changes: index terms, description and conditions
  4. Oct 16, 2026
    Eligibility 5 criteria added
    What changed in the criteria
    • AddedExclusion Criteria:
    • AddedA patient will be considered inelligibe for this study if any of the following conditions apply:
    • AddedSynchronous malignancy
    • AddedHereditary cancer syndromes
    • AddedHistory of Inflammatory bowel disease
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07619079
Responsible party
Sponsor
First posted
Jun 1, 2026
Start date
May 19, 2026
Primary completion
May 19, 2029 (estimated)
Completion
May 19, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Georgios Karagkounis, MD
Contact
karagkog@mskcc.org
212-639-2269
Julio Garcia-Aguilar, MD, PhD
Contact
212 639 5117
Georgios Karagkounis, MD
principal investigator · Memorial Sloan Kettering Cancer Center

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion